The Experts below are selected from a list of 27810 Experts worldwide ranked by ideXlab platform
Jose G. Montoya - One of the best experts on this subject based on the ideXlab platform.
-
use of valganciclovir in patients with elevated antibody titers against human herpesvirus 6 hhv 6 and epstein barr virus ebv who were experiencing central Nervous System Dysfunction including long standing fatigue
Journal of Clinical Virology, 2006Co-Authors: Andreas M. Kogelnik, Kristin S. Loomis, Fernando Rosso, Courtney Hischier, Jose G. Montoya, Mette HoeghpetersenAbstract:Background Twelve patients with long-standing symptoms of central Nervous System (CNS) Dysfunction were found to have elevated antibody titres to human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV). All patients had four or more of the following neurocognitive symptoms: impaired cognitive functioning, slowed processing speed, sleep disturbance, short-term memory deficit, fatigue and symptoms consistent with depression. Objectives We sought to determine whether elevated antibodies to EBV and HHV-6 indicated chronic viral activation in patients with CNS Dysfunction and if their symptoms could be improved by suppressing viral activity with oral valganciclovir. Study design Patients with high IgG antibody titers against HHV-6 and EBV who were suffering from central Nervous System Dysfunction and debilitating fatigue for more than one year (median 3 years, range 1-8 years) were treated with 6 months of valganciclovir in an open label study. Results Nine out of 12 (75%) patients experienced near resolution of their symptoms, allowing them all to return to the workforce or full time activites. In the nine patients with a symptomatic response to treatment, EBV VCA IgG titers dropped from 1:2560 to 1:640 (p = 0.008) and HHV-6 IgG titers dropped from a median value of 1:1280 to 1:320 (p = 0.271). Clinically significant hematological toxicity or serious adverse events were not observed among the 12 patients. Conclusion These preliminary clinical and laboratory observations merit additional studies to establish whether this clinical response is mediated by an antiviral effect of the drug, indirectly via immunomodulation or by placebo effect.
-
Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein—Barr Virus (EBV) who were experiencing central Nervous System Dysfunction including long-standing fatigue
Journal of Clinical Virology, 2006Co-Authors: Andreas M. Kogelnik, Kristin S. Loomis, Mette Hoegh-petersen, Fernando Rosso, Courtney Hischier, Jose G. MontoyaAbstract:Background Twelve patients with long-standing symptoms of central Nervous System (CNS) Dysfunction were found to have elevated antibody titres to human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV). All patients had four or more of the following neurocognitive symptoms: impaired cognitive functioning, slowed processing speed, sleep disturbance, short-term memory deficit, fatigue and symptoms consistent with depression. Objectives We sought to determine whether elevated antibodies to EBV and HHV-6 indicated chronic viral activation in patients with CNS Dysfunction and if their symptoms could be improved by suppressing viral activity with oral valganciclovir. Study design Patients with high IgG antibody titers against HHV-6 and EBV who were suffering from central Nervous System Dysfunction and debilitating fatigue for more than one year (median 3 years, range 1-8 years) were treated with 6 months of valganciclovir in an open label study. Results Nine out of 12 (75%) patients experienced near resolution of their symptoms, allowing them all to return to the workforce or full time activites. In the nine patients with a symptomatic response to treatment, EBV VCA IgG titers dropped from 1:2560 to 1:640 (p = 0.008) and HHV-6 IgG titers dropped from a median value of 1:1280 to 1:320 (p = 0.271). Clinically significant hematological toxicity or serious adverse events were not observed among the 12 patients. Conclusion These preliminary clinical and laboratory observations merit additional studies to establish whether this clinical response is mediated by an antiviral effect of the drug, indirectly via immunomodulation or by placebo effect.
-
Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central Nervous System Dysfunction including long-standing fatigue.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2006Co-Authors: Andreas M. Kogelnik, Mette Hoegh-petersen, Fernando Rosso, Courtney Hischier, Kristin Loomis, Jose G. MontoyaAbstract:Twelve patients with long-standing symptoms of central Nervous System (CNS) Dysfunction were found to have elevated antibody titres to human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV). All patients had four or more of the following neurocognitive symptoms: impaired cognitive functioning, slowed processing speed, sleep disturbance, short-term memory deficit, fatigue and symptoms consistent with depression. We sought to determine whether elevated antibodies to EBV and HHV-6 indicated chronic viral activation in patients with CNS Dysfunction and if their symptoms could be improved by suppressing viral activity with oral valganciclovir. Patients with high IgG antibody titers against HHV-6 and EBV who were suffering from central Nervous System Dysfunction and debilitating fatigue for more than one year (median 3 years, range 1-8 years) were treated with 6 months of valganciclovir in an open label study. Nine out of 12 (75%) patients experienced near resolution of their symptoms, allowing them all to return to the workforce or full time activites. In the nine patients with a symptomatic response to treatment, EBV VCA IgG titers dropped from 1:2560 to 1:640 (p = 0.008) and HHV-6 IgG titers dropped from a median value of 1:1280 to 1:320 (p = 0.271). Clinically significant hematological toxicity or serious adverse events were not observed among the 12 patients. These preliminary clinical and laboratory observations merit additional studies to establish whether this clinical response is mediated by an antiviral effect of the drug, indirectly via immunomodulation or by placebo effect.
Kazuyuki Shimada - One of the best experts on this subject based on the ideXlab platform.
-
autonomic Nervous System Dysfunction in elderly hypertensive patients with abnormal diurnal blood pressure variation relation to silent cerebrovascular disease
Hypertension, 1997Co-Authors: Kazuomi Kario, Keiji Motai, Takeshi Mitsuhashi, Takaaki Suzuki, Yukinori Nakagawa, Uichi Ikeda, Takefumi Matsuo, Toshio Nakayama, Kazuyuki ShimadaAbstract:Abstract To investigate the relationships among diurnal blood pressure (BP) variations and autonomic Nervous System Dysfunction, we assessed heart rate variability (HRV) using power spectral analysis of the 24-hour RR interval in 51 asymptomatic elderly hypertensive patients with various patterns of nocturnal BP fall. The extreme-dippers with marked nocturnal BP fall (n=16) had lower asleep low-frequency power (LF)/high-frequency power (HF) ratios (a relative index of sympathetic Nervous System activity), while the nondippers without nocturnal BP fall (n=18) had lower awake LF/HF ratios and asleep/awake ratio for HF (an index of parasympathetic Nervous activity), when compared with dippers with appropriate nocturnal BP fall (n=17). The incidence of multiple lacunar infarction detected by brain magnetic resonance imaging was 56% in the extreme-dippers and 38% in the nondippers, and both were markedly higher than that (6.3%) in the dippers (both P r =−.363, P r =.540, P
-
autonomic Nervous System Dysfunction in elderly hypertensive patients with abnormal diurnal blood pressure variation relation to silent cerebrovascular disease
Hypertension, 1997Co-Authors: Kazuomi Kario, Keiji Motai, Takeshi Mitsuhashi, Takaaki Suzuki, Yukinori Nakagawa, Uichi Ikeda, Takefumi Matsuo, Toshio Nakayama, Kazuyuki ShimadaAbstract:To investigate the relationships among diurnal blood pressure (BP) variations and autonomic Nervous System Dysfunction, we assessed heart rate variability (HRV) using power spectral analysis of the 24-hour RR interval in 51 asymptomatic elderly hypertensive patients with various patterns of nocturnal BP fall. The extreme-dippers with marked nocturnal BP fall (n=16) had lower asleep low-frequency power (LF)/high-frequency power (HF) ratios (a relative index of sympathetic Nervous System activity), while the nondippers without nocturnal BP fall (n=18) had lower awake LF/HF ratios and asleep/awake ratio for HF (an index of parasympathetic Nervous activity), when compared with dippers with appropriate nocturnal BP fall (n=17). The incidence of multiple lacunar infarction detected by brain magnetic resonance imaging was 56% in the extreme-dippers and 38% in the nondippers, and both were markedly higher than that (6.3%) in the dippers (both P<.01). There was no significant relationship between the BP level and any HRV parameter for either the daytime or nighttime period. The asleep/awake ratio for systolic BP was significantly correlated with the asleep/awake ratio for HF (r= -.363, P<.01) and with the asleep/awake ratio for the LF/HF ratio (r=.540, P<.001), regardless of whether multiple lacunar infarction was present. In conclusion, the autonomic Nervous System activity is not related to high BP level per se, rather its diurnal variation is more important as a determinant of the diurnal BP patterns, regardless of the presence or absence of cerebrovascular disease.
Kazuomi Kario - One of the best experts on this subject based on the ideXlab platform.
-
autonomic Nervous System Dysfunction in elderly hypertensive patients with abnormal diurnal blood pressure variation relation to silent cerebrovascular disease
Hypertension, 1997Co-Authors: Kazuomi Kario, Keiji Motai, Takeshi Mitsuhashi, Takaaki Suzuki, Yukinori Nakagawa, Uichi Ikeda, Takefumi Matsuo, Toshio Nakayama, Kazuyuki ShimadaAbstract:Abstract To investigate the relationships among diurnal blood pressure (BP) variations and autonomic Nervous System Dysfunction, we assessed heart rate variability (HRV) using power spectral analysis of the 24-hour RR interval in 51 asymptomatic elderly hypertensive patients with various patterns of nocturnal BP fall. The extreme-dippers with marked nocturnal BP fall (n=16) had lower asleep low-frequency power (LF)/high-frequency power (HF) ratios (a relative index of sympathetic Nervous System activity), while the nondippers without nocturnal BP fall (n=18) had lower awake LF/HF ratios and asleep/awake ratio for HF (an index of parasympathetic Nervous activity), when compared with dippers with appropriate nocturnal BP fall (n=17). The incidence of multiple lacunar infarction detected by brain magnetic resonance imaging was 56% in the extreme-dippers and 38% in the nondippers, and both were markedly higher than that (6.3%) in the dippers (both P r =−.363, P r =.540, P
-
autonomic Nervous System Dysfunction in elderly hypertensive patients with abnormal diurnal blood pressure variation relation to silent cerebrovascular disease
Hypertension, 1997Co-Authors: Kazuomi Kario, Keiji Motai, Takeshi Mitsuhashi, Takaaki Suzuki, Yukinori Nakagawa, Uichi Ikeda, Takefumi Matsuo, Toshio Nakayama, Kazuyuki ShimadaAbstract:To investigate the relationships among diurnal blood pressure (BP) variations and autonomic Nervous System Dysfunction, we assessed heart rate variability (HRV) using power spectral analysis of the 24-hour RR interval in 51 asymptomatic elderly hypertensive patients with various patterns of nocturnal BP fall. The extreme-dippers with marked nocturnal BP fall (n=16) had lower asleep low-frequency power (LF)/high-frequency power (HF) ratios (a relative index of sympathetic Nervous System activity), while the nondippers without nocturnal BP fall (n=18) had lower awake LF/HF ratios and asleep/awake ratio for HF (an index of parasympathetic Nervous activity), when compared with dippers with appropriate nocturnal BP fall (n=17). The incidence of multiple lacunar infarction detected by brain magnetic resonance imaging was 56% in the extreme-dippers and 38% in the nondippers, and both were markedly higher than that (6.3%) in the dippers (both P<.01). There was no significant relationship between the BP level and any HRV parameter for either the daytime or nighttime period. The asleep/awake ratio for systolic BP was significantly correlated with the asleep/awake ratio for HF (r= -.363, P<.01) and with the asleep/awake ratio for the LF/HF ratio (r=.540, P<.001), regardless of whether multiple lacunar infarction was present. In conclusion, the autonomic Nervous System activity is not related to high BP level per se, rather its diurnal variation is more important as a determinant of the diurnal BP patterns, regardless of the presence or absence of cerebrovascular disease.
Fernando Rosso - One of the best experts on this subject based on the ideXlab platform.
-
use of valganciclovir in patients with elevated antibody titers against human herpesvirus 6 hhv 6 and epstein barr virus ebv who were experiencing central Nervous System Dysfunction including long standing fatigue
Journal of Clinical Virology, 2006Co-Authors: Andreas M. Kogelnik, Kristin S. Loomis, Fernando Rosso, Courtney Hischier, Jose G. Montoya, Mette HoeghpetersenAbstract:Background Twelve patients with long-standing symptoms of central Nervous System (CNS) Dysfunction were found to have elevated antibody titres to human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV). All patients had four or more of the following neurocognitive symptoms: impaired cognitive functioning, slowed processing speed, sleep disturbance, short-term memory deficit, fatigue and symptoms consistent with depression. Objectives We sought to determine whether elevated antibodies to EBV and HHV-6 indicated chronic viral activation in patients with CNS Dysfunction and if their symptoms could be improved by suppressing viral activity with oral valganciclovir. Study design Patients with high IgG antibody titers against HHV-6 and EBV who were suffering from central Nervous System Dysfunction and debilitating fatigue for more than one year (median 3 years, range 1-8 years) were treated with 6 months of valganciclovir in an open label study. Results Nine out of 12 (75%) patients experienced near resolution of their symptoms, allowing them all to return to the workforce or full time activites. In the nine patients with a symptomatic response to treatment, EBV VCA IgG titers dropped from 1:2560 to 1:640 (p = 0.008) and HHV-6 IgG titers dropped from a median value of 1:1280 to 1:320 (p = 0.271). Clinically significant hematological toxicity or serious adverse events were not observed among the 12 patients. Conclusion These preliminary clinical and laboratory observations merit additional studies to establish whether this clinical response is mediated by an antiviral effect of the drug, indirectly via immunomodulation or by placebo effect.
-
Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein—Barr Virus (EBV) who were experiencing central Nervous System Dysfunction including long-standing fatigue
Journal of Clinical Virology, 2006Co-Authors: Andreas M. Kogelnik, Kristin S. Loomis, Mette Hoegh-petersen, Fernando Rosso, Courtney Hischier, Jose G. MontoyaAbstract:Background Twelve patients with long-standing symptoms of central Nervous System (CNS) Dysfunction were found to have elevated antibody titres to human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV). All patients had four or more of the following neurocognitive symptoms: impaired cognitive functioning, slowed processing speed, sleep disturbance, short-term memory deficit, fatigue and symptoms consistent with depression. Objectives We sought to determine whether elevated antibodies to EBV and HHV-6 indicated chronic viral activation in patients with CNS Dysfunction and if their symptoms could be improved by suppressing viral activity with oral valganciclovir. Study design Patients with high IgG antibody titers against HHV-6 and EBV who were suffering from central Nervous System Dysfunction and debilitating fatigue for more than one year (median 3 years, range 1-8 years) were treated with 6 months of valganciclovir in an open label study. Results Nine out of 12 (75%) patients experienced near resolution of their symptoms, allowing them all to return to the workforce or full time activites. In the nine patients with a symptomatic response to treatment, EBV VCA IgG titers dropped from 1:2560 to 1:640 (p = 0.008) and HHV-6 IgG titers dropped from a median value of 1:1280 to 1:320 (p = 0.271). Clinically significant hematological toxicity or serious adverse events were not observed among the 12 patients. Conclusion These preliminary clinical and laboratory observations merit additional studies to establish whether this clinical response is mediated by an antiviral effect of the drug, indirectly via immunomodulation or by placebo effect.
-
Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central Nervous System Dysfunction including long-standing fatigue.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2006Co-Authors: Andreas M. Kogelnik, Mette Hoegh-petersen, Fernando Rosso, Courtney Hischier, Kristin Loomis, Jose G. MontoyaAbstract:Twelve patients with long-standing symptoms of central Nervous System (CNS) Dysfunction were found to have elevated antibody titres to human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV). All patients had four or more of the following neurocognitive symptoms: impaired cognitive functioning, slowed processing speed, sleep disturbance, short-term memory deficit, fatigue and symptoms consistent with depression. We sought to determine whether elevated antibodies to EBV and HHV-6 indicated chronic viral activation in patients with CNS Dysfunction and if their symptoms could be improved by suppressing viral activity with oral valganciclovir. Patients with high IgG antibody titers against HHV-6 and EBV who were suffering from central Nervous System Dysfunction and debilitating fatigue for more than one year (median 3 years, range 1-8 years) were treated with 6 months of valganciclovir in an open label study. Nine out of 12 (75%) patients experienced near resolution of their symptoms, allowing them all to return to the workforce or full time activites. In the nine patients with a symptomatic response to treatment, EBV VCA IgG titers dropped from 1:2560 to 1:640 (p = 0.008) and HHV-6 IgG titers dropped from a median value of 1:1280 to 1:320 (p = 0.271). Clinically significant hematological toxicity or serious adverse events were not observed among the 12 patients. These preliminary clinical and laboratory observations merit additional studies to establish whether this clinical response is mediated by an antiviral effect of the drug, indirectly via immunomodulation or by placebo effect.
Andreas M. Kogelnik - One of the best experts on this subject based on the ideXlab platform.
-
use of valganciclovir in patients with elevated antibody titers against human herpesvirus 6 hhv 6 and epstein barr virus ebv who were experiencing central Nervous System Dysfunction including long standing fatigue
Journal of Clinical Virology, 2006Co-Authors: Andreas M. Kogelnik, Kristin S. Loomis, Fernando Rosso, Courtney Hischier, Jose G. Montoya, Mette HoeghpetersenAbstract:Background Twelve patients with long-standing symptoms of central Nervous System (CNS) Dysfunction were found to have elevated antibody titres to human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV). All patients had four or more of the following neurocognitive symptoms: impaired cognitive functioning, slowed processing speed, sleep disturbance, short-term memory deficit, fatigue and symptoms consistent with depression. Objectives We sought to determine whether elevated antibodies to EBV and HHV-6 indicated chronic viral activation in patients with CNS Dysfunction and if their symptoms could be improved by suppressing viral activity with oral valganciclovir. Study design Patients with high IgG antibody titers against HHV-6 and EBV who were suffering from central Nervous System Dysfunction and debilitating fatigue for more than one year (median 3 years, range 1-8 years) were treated with 6 months of valganciclovir in an open label study. Results Nine out of 12 (75%) patients experienced near resolution of their symptoms, allowing them all to return to the workforce or full time activites. In the nine patients with a symptomatic response to treatment, EBV VCA IgG titers dropped from 1:2560 to 1:640 (p = 0.008) and HHV-6 IgG titers dropped from a median value of 1:1280 to 1:320 (p = 0.271). Clinically significant hematological toxicity or serious adverse events were not observed among the 12 patients. Conclusion These preliminary clinical and laboratory observations merit additional studies to establish whether this clinical response is mediated by an antiviral effect of the drug, indirectly via immunomodulation or by placebo effect.
-
Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein—Barr Virus (EBV) who were experiencing central Nervous System Dysfunction including long-standing fatigue
Journal of Clinical Virology, 2006Co-Authors: Andreas M. Kogelnik, Kristin S. Loomis, Mette Hoegh-petersen, Fernando Rosso, Courtney Hischier, Jose G. MontoyaAbstract:Background Twelve patients with long-standing symptoms of central Nervous System (CNS) Dysfunction were found to have elevated antibody titres to human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV). All patients had four or more of the following neurocognitive symptoms: impaired cognitive functioning, slowed processing speed, sleep disturbance, short-term memory deficit, fatigue and symptoms consistent with depression. Objectives We sought to determine whether elevated antibodies to EBV and HHV-6 indicated chronic viral activation in patients with CNS Dysfunction and if their symptoms could be improved by suppressing viral activity with oral valganciclovir. Study design Patients with high IgG antibody titers against HHV-6 and EBV who were suffering from central Nervous System Dysfunction and debilitating fatigue for more than one year (median 3 years, range 1-8 years) were treated with 6 months of valganciclovir in an open label study. Results Nine out of 12 (75%) patients experienced near resolution of their symptoms, allowing them all to return to the workforce or full time activites. In the nine patients with a symptomatic response to treatment, EBV VCA IgG titers dropped from 1:2560 to 1:640 (p = 0.008) and HHV-6 IgG titers dropped from a median value of 1:1280 to 1:320 (p = 0.271). Clinically significant hematological toxicity or serious adverse events were not observed among the 12 patients. Conclusion These preliminary clinical and laboratory observations merit additional studies to establish whether this clinical response is mediated by an antiviral effect of the drug, indirectly via immunomodulation or by placebo effect.
-
Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central Nervous System Dysfunction including long-standing fatigue.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2006Co-Authors: Andreas M. Kogelnik, Mette Hoegh-petersen, Fernando Rosso, Courtney Hischier, Kristin Loomis, Jose G. MontoyaAbstract:Twelve patients with long-standing symptoms of central Nervous System (CNS) Dysfunction were found to have elevated antibody titres to human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV). All patients had four or more of the following neurocognitive symptoms: impaired cognitive functioning, slowed processing speed, sleep disturbance, short-term memory deficit, fatigue and symptoms consistent with depression. We sought to determine whether elevated antibodies to EBV and HHV-6 indicated chronic viral activation in patients with CNS Dysfunction and if their symptoms could be improved by suppressing viral activity with oral valganciclovir. Patients with high IgG antibody titers against HHV-6 and EBV who were suffering from central Nervous System Dysfunction and debilitating fatigue for more than one year (median 3 years, range 1-8 years) were treated with 6 months of valganciclovir in an open label study. Nine out of 12 (75%) patients experienced near resolution of their symptoms, allowing them all to return to the workforce or full time activites. In the nine patients with a symptomatic response to treatment, EBV VCA IgG titers dropped from 1:2560 to 1:640 (p = 0.008) and HHV-6 IgG titers dropped from a median value of 1:1280 to 1:320 (p = 0.271). Clinically significant hematological toxicity or serious adverse events were not observed among the 12 patients. These preliminary clinical and laboratory observations merit additional studies to establish whether this clinical response is mediated by an antiviral effect of the drug, indirectly via immunomodulation or by placebo effect.
